Armistice Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Armistice Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.6M	Buy	1,280,000 +444,000	+53%	+$14.9M	0.62%	26
2025 Q4	$35.8M	Buy	836,000 +112,000	+15%	+$4.22M	0.43%	40
2025 Q3	$20.5M	Sell	724,000 -876,000	-55%	-$26.2M	0.3%	51
2025 Q2	$30M	Buy	1,600,000 +84,000	+6%	+$1.59M	0.52%	31
2025 Q1	$27.3M	Buy	1,516,000 +364,000	+32%	+$7.39M	0.41%	51
2024 Q4	$19.4M	Sell	1,152,000 -384,000	-25%	-$7.36M	0.26%	78
2024 Q3	$24.9M	Sell	1,536,000 -88,000	-5%	-$1.03M	0.4%	46
2024 Q2	$13.3M	Buy	1,624,000 +88,000	+6%	+$921K	0.17%	83
2024 Q1	$22.7M	Sell	1,536,000 -174,000	-10%	-$2.34M	0.3%	55
2023 Q4	$24.8M	Sell	1,710,000 -3,600	-0.2%	-$36.8K	0.34%	52
2023 Q3	$18.5M	Buy	1,713,600 +3,600	+0.2%	+$43.3K	0.28%	62
2023 Q2	$22.1M	Buy	1,710,000 +7,600	+0.4%	+$103K	0.32%	60
2023 Q1	$22.5M	Buy	1,702,400 +6,800	+0.4%	+$108K	0.32%	58
2022 Q4	$25.4M	Buy	1,695,600 +1,350,313	+391%	+$12.4M	0.44%	45
2022 Q3	$4.07M	Buy	+345,287	New	+$4.67M	0.07%	103
2020 Q3	–	Sell	-52,270	Closed	-$957K	–	118
2020 Q2	$957K	Buy	+52,270	New	+$940K	0.04%	78

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Armistice Capital's RIGL Position: Q1 2026 in Review

Armistice Capital increased its Rigel Pharmaceuticals (RIGL) stake by 53% in Q1 2026, buying an estimated $14.9M and bringing the position to 1,280,000 shares worth $34.6M. The position accounts for 0.62% of the portfolio, ranked #26.

Armistice Capital first reported a position in RIGL in Q2 2020 and has held it in 16 quarters since. The position peaked at $35.8M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

Armistice Capital held 1,280,000 shares of Rigel Pharmaceuticals worth $34.6M as of Q1 2026.
Armistice Capital bought 444,000 Rigel Pharmaceuticals shares in Q1 2026, an estimated $14.9M.
Rigel Pharmaceuticals made up 0.62% of Armistice Capital's portfolio in Q1 2026, its #26 holding.
Armistice Capital first reported a position in Rigel Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
Armistice Capital's Rigel Pharmaceuticals position peaked at $35.8M in Q4 2025.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.